Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00344539 · ClinicalTrials.gov registry record · Phase 1
AMA1-C1/Alhydrogel + CpG 7909 for Malaria
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00344539 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 75 participants.
The verdict
NCT00344539, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to test an experimental malaria vaccine in about 75 healthy adults, 18-45 years of age. The study will also test an experimental adjuvant which is a material added to a vaccine to help the body make more defense cells. The body's immune response (response to foreign substances) and the safety of the vaccine will be tested. All subjects will receive 3 doses of vaccine on days 0, 28, and 56 and doses may increase during the study. Participation in the study is expected to be up to 323 days and includes 16 visits. Study procedures include medical history, physical exams, urine and blood testing.
Interventions
- BIOLOGICAL AMA1-C1/Alhydrogel®
- BIOLOGICAL CPG 7909 Oligodeoxynucleotide (VaxImmune®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00344539
The ClinicalTrials.gov registry entry for NCT00344539 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMA1-C1/Alhydrogel® is the first listed.
NCT00344539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00344539 about?
NCT00344539 is a clinical study titled "AMA1-C1/Alhydrogel + CpG 7909 for Malaria". The purpose of this study is to test an experimental malaria vaccine in about 75 healthy adults, 18-45 years of age. The study will also test an experimental adjuvant which is a material added to a vaccine to help the body make more defense cells. The body's immune response (response to foreign subs...
What is the current status of trial NCT00344539?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2005-05. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00344539?
The interventions under investigation include: AMA1-C1/Alhydrogel® (BIOLOGICAL), CPG 7909 Oligodeoxynucleotide (VaxImmune®) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00344539?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.